COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma (CLEAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01766583
Recruitment Status : Completed
First Posted : January 11, 2013
Last Update Posted : March 7, 2018
Celgene Corporation
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:
This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292 and lenalidomide combination therapy. Subjects will be followed for disease progression and collection of second primary malignancy (SPM) events. This dose escalation will be followed by an exploratory expansion phase in 3 cohorts of 12 patients each.

Condition or disease Intervention/treatment Phase
Relapsed/Refractory B-cell Lymphoma Drug: CC-292 + lenalidomide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : February 2013
Actual Primary Completion Date : November 2014
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: CC-292 + lenalidomide
Combination of CC-292 + lenalidomide
Drug: CC-292 + lenalidomide
CC-292 + lenalidomide

Primary Outcome Measures :
  1. Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma [ Time Frame: 28 days ]
    The optimal CC-292 and lenalidomide combination will be determined based on the maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and/or the analysis of adverse events, serious adverse events and toxicities observed during the study

Secondary Outcome Measures :
  1. preliminary efficacy signals of the CC-292 + Lenalidomide combination [ Time Frame: 6 months ]
    Overall response rate and overall response rate, complete and partial response rates, progression free survival, response duration, time to next treatment and overall survival

  2. Observed maximum plasma concentration [ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose ]
  3. time to reach maximum observed plasma concentration (Tmax) [ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose ]
  4. Terminal phase rate constant (λz) [ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose ]
  5. plasma decay half-life (t1/2) [ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose ]
  6. Area under the curve from time zero to the last quantifiable concentration [AUC(0-t)] [ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose ]
    Area under the plasma concentration versus time curve from time zero (predose) to time of the last quantifiable concentration (0-t)

  7. Area under the curve from time zero to extrapolated infinity [AUC(0-∞)] [ Time Frame: 0, 0.5, 1, 2, 4, 6, 8 hours post dose ]
    Area under the plasma concentration versus time curve (AUC) from time zero (predose)to extrapolated infinity(0-∞)

  8. BTk receptor occupancy [ Time Frame: 0 (predose) and 21 days post dose ]
    BTK receptor occupancy will be determined in the peripheral blood cells and tumor tissue

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histology:

    1. Patients with any type of B-cell Lymphoma except CLL, SLL and Waldenström disease will be eligible during the dose escalation phase
    2. During the expansion phases, patients with DLBCL for cohort A, mantle cell lymphoma for cohort B and any other type of B-cell lymphoma except CLL, SLL and Waldenström disease for cohort C.
  • Other criteria:

    • Signed inform consent
    • Patients should be relapsed or refractory NHL after ≥1 prior Rituximab-containing regimen for which no other type of therapy is of higher priority
    • Aged 18 years or more.
    • ECOG performance status 0-2.
    • Measurable disease defined by at least one single node or tumor lesion > 1.5 cm.
    • Life expectancy of ≥ 90 days (3 months).
    • Patients must be eligible and willing to undergo excisional biopsies of tumor sites with a lymph node of minimum 1 cm at baseline and after 21 days of treatment
    • Females of childbearing potential (FCBP)† must have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL before starting lenalidomide - the first test must be performed within 10-14 days before starting lenalidomide treatment and the second test must be performed within 24 hours before starting lenalidomide
    • FCBP must either commit to continued abstinence from heterosexual intercourse or begin two methods of birth control, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to monthly pregnancy testing and must be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.
    • Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential. Men must also be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.

Exclusion Criteria:

Previous treatment with lenalidomide or a BTK inhibitor. Central nervous system or meningeal involvement. Contraindication to any drug contained in this regimen Concomitant use of medicines known to cause QT prolongation or torsades de pointes HIV disease, active hepatitis B or C. Any serious active disease or co-morbid medical condition (according to investigator's decision);

Any of the following laboratory abnormalities :

  • Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L).
  • Platelet count < 80,000/mm3 (80 x 109/L)
  • Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN).
  • Serum total bilirubin > 1.5 ULN except in case of hemolytic anemia and Gilbert's syndrome.

Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of < 50 mL /min Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast or Incidental histological finding of prostate cancer [TNM stage of T1a or T1b]) unless the subject has been free of the disease for ≥ 5 years Any serious medical condition, laboratory abnormality, or psychiatric illnessthat would prevent the subject from signing the informed consent form.

Pregnant or lactating females. Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide and/or pomalidomide.

Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide and/or pomalidomide.

Subjects with ≥ Grade 2 neuropathy. Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug therapy.

Chronic use of proton pump inhibitors, H2 antagonists or antacids or their use in the last 7 days prior to the first CC-292 dose. Patients with chronic gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease, should be carefully evaluated for their suitability for this treatment prior to enrollment in this study. These medications should be avoided throughout the study.

Patients taking corticosteroids during the 4 weeks prior to inclusion, unless administered at a dose equivalent of ≤ 10 mg/day prednisone (over these 4 weeks).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01766583

Layout table for location information
Hopital henri mondor
Créteil, France, 94010
CHU de Lille
Lille, France, 59037
Institut Paoli Calmette
Marseille, France, 13273
CHU de Nantes
Nantes, France, 44093
CHU Lyon Sud
Pierre Bénite, France, 69495
CHU de Toulouse
Toulouse, France, 31059
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Celgene Corporation
Layout table for investigator information
Study Chair: Gilles Salles, PhD CHU Lyon - Sud - LYSA
Study Chair: Loïc YSEBAERT, MD CHU de Toulouse LYSA
Additional Information:
Layout table for additonal information
Responsible Party: The Lymphoma Academic Research Organisation Identifier: NCT01766583    
Other Study ID Numbers: CLEAR
First Posted: January 11, 2013    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: March 2018
Keywords provided by The Lymphoma Academic Research Organisation:
Open label, 3 + 3 dose escalation study followed by an expansion phase.
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents